| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 98.20 mm | 98.20 mm | 98.20 mm | 98.20 mm | 98.20 mm | 98.20 mm |
| Cash burn (monthly) | 16.60 mm | 2.87 mm | 12.23 mm | 1.90 mm | 11.34 mm | 13.27 mm |
| Cash used (since last report) | 84.35 mm | 14.57 mm | 62.13 mm | 9.64 mm | 57.65 mm | 67.45 mm |
| Cash remaining | 13.85 mm | 83.63 mm | 36.07 mm | 88.56 mm | 40.55 mm | 30.75 mm |
| Runway (months of cash) | 0.8 | 29.2 | 2.9 | 46.7 | 3.6 | 2.3 |
| 13F holders | Current |
|---|---|
| Total holders | 105 |
| Opened positions | 13 |
| Closed positions | 13 |
| Increased positions | 34 |
| Reduced positions | 18 |
| 13F shares | Current |
|---|---|
| Total value | 66.58 bn |
| Total shares | 143.62 mm |
| Total puts | 50.60 k |
| Total calls | 213.40 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Bain Capital Life Sciences Fund | 16.92 mm | $0.00 |
| Bain Capital Life Sciences Investors | 16.92 mm | $11.32 bn |
| Growth Equity Opportunities 18 VGE | 15.74 mm | $30.54 mm |
| NEA Management | 14.99 mm | $10.04 bn |
| BlackRock | 11.21 mm | $7.50 bn |
| Vanguard | 8.44 mm | $5.65 bn |
| Orbimed Advisors | 7.13 mm | $4.77 bn |
| Kingdon Capital Management, L.L.C. | 4.64 mm | $3.10 bn |
| Empery Asset Management | 4.55 mm | $0.00 |
| Adage Capital Partners GP, L.L.C. | 4.28 mm | $2.86 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Feb 25 | Arbet-Engels Christophe | Common Stock | Grant | Acquire A | No | No | 0 | 850,000 | 0.00 | 864,207 |
| 12 Feb 25 | Mostafa Adam S. | Common Stock | Grant | Acquire A | No | No | 0 | 850,000 | 0.00 | 850,000 |
| 12 Feb 25 | Ragan Paula | Common Stock | Grant | Acquire A | No | No | 0 | 2,250,000 | 0.00 | 3,337,386 |
| 12 Feb 25 | Mary DiBiase | Common Stock | Grant | Acquire A | No | No | 0 | 650,000 | 0.00 | 1,140,980 |
| 24 Jan 25 | Mary DiBiase | Common Stock | Sell | Dispose S | No | Yes | 0.4535 | 22,258 | 10.09 k | 490,980 |
| 23 Jan 25 | Mary DiBiase | Common Stock | Grant | Acquire A | No | No | 0 | 61,178 | 0.00 | 513,238 |
